Eurofins Launches a Buy-Back Programme of Its Own Shares

Regulatory News:

Eurofins Scientific SE (the “Company”) (EUFI.PA) (Paris:ERF) announces its intention to buy-back some of its own shares (ISIN FR0014000MR3) for a maximum amount representing up to 2% of its share capital, over a maximum period of twelve months, as per the authorisation granted by the Company’s Extraordinary General Meeting of shareholders held on 25 April 2019. The Company may at any time interrupt this programme in view of market conditions and/or investment strategy evolution.

The shares to be purchased under this programme will be primarily used to hedge the Company’s Long-Term Incentive plans but may also be cancelled or used to partially finance acquisitions.

The Company has mandated an independent provider of financial services to execute the first tranche of this programme for a duration of maximum two months and a maximum amount representing up to one million shares or 0.52% of its share capital. The exact quantum and purpose allocation of the bought-back shares will be communicated at the end of this first tranche.

Notes to Editors:

For more information, please visit www.eurofins.com.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a decentralised and entrepreneurial network of 940 laboratories in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.